定量聚合酶链反应检测肝病患者血清HBV DNA及治疗意义

Detection of Serum HBV DNA of Patients with Hepatic Diseases by Quantitative PCR and the Significance to Therapy

本文采用定量聚合酶链反应（PCR）检测了327例乙型肝炎及肝癌患者血清HBVDNA含量和部分病例治疗前后其含量的变化。结果显示，但肝组＞急肝组，且均明显高于肝硬化组，肝癌组与肝硬化组相似；HBeAg（+）组血清HBVDNA含量明显高于HBeAg（-）组；血清HBVDNA含量与黄疸及转氨酶无关。特异性过继细胞免疫疗法治疗后完全反应者、部分反应者及无反应者其血清HBVDNA含量变化不同。结果表明：血清HBVDNA含量高低与肝炎疾病进展程度呈一定的相关性，而与肝细胞损伤程度无关；定量检测HBVDNA含量是评价特异性过继细胞免疫疗法疗效的重要指标之一。

The HBV DNA in sera of patients with hepatis B and hepatoma was detected by a quantitive PCR assay,some of which included sera at the beginning and end of specific adoptive cellular immunotherapy.The results showed that the concertrtions of chronic,acute and severe hepatis groups were higher than those of the group,of which those of chronic group were highest, the severe group lowest,but those of hepatoma group were similar to those of cirrhosis group. The concertrations in HBeAg-positive group were higher than those in HBeAg negative one, those of HBV DNA wer not related to ALT levels and jaundice degree. The certrations of viral DNA in long term responders, shart - time rdsponders and nonsponders after therapy obviously changed. These results demonstrted that the concentrations of HBV DNA in serum seemed to be related to the developed clinic stage of hepatitis, not related to hepatic injures;detection of HBV DNA by a quantitative PCR assay was one of the important indexes for evaluating the effect of therpy.